专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4342478A1 PREVENTIVE AGENT AND/OR THERAPEUTIC AGENT FOR BEDSORES 审中-实审
公开(公告)号：EP4342478A1
公开(公告)日：2024-03-27
申请号：EP22804760.1
申请日：2022-05-19
申请人： Tokyo Medical University , Cysay Inc.
发明人： YOSHIMOTO Takayuki , KATAHIRA Yasuhiro , YAMASHITA Yasuhiro
IPC分类号： A61K35/28 , A61K9/06 , A61K9/08 , A61K9/107 , A61K9/19 , A61K35/32 , A61K38/19 , A61P17/00
摘要： The object of the present invention is to provide a preventive and/or therapeutic agent for pressure ulcers comprising a conditioned medium of immortalized mesenchymal stem cells to which specific genes are introduced as an active ingredient.
The present invention provides the preventive and/or therapeutic agent for pressure ulcers comprising the conditioned medium of immortalized mesenchymal stem cells, to which hTERT or pTERT gene, bmi-1 gene, HPV-E6 gene, and HPV-E7 gene are introduced, as an active ingredient. Here, the mesenchymal stem cells are preferably obtained from either human or swine. The conditioned medium preferably contains at least three or more cytokines selected from the group consisting of insulin-like growth factor binding protein, metalloproteinase tissue inhibitor, vascular endothelial growth factor, hepatocyte growth factor, tumor necrosis factor receptor II, and osteoprotegerin/osteoclast differentiation inhibitory factor; and each in the concentration range thereof is from 1 x 10 3 to 1 x 10 6 pg/mL, respectively.

2. 发明公开

EP4245854A1 MIR-29A-LIKE NUCLEIC ACID REAGENT, LIVER FIBROSIS INHIBITOR, AND PHARMACEUTICAL COMPOSITION 审中-实审
公开(公告)号：EP4245854A1
公开(公告)日：2023-09-20
申请号：EP21891887.8
申请日：2021-11-10
申请人： TOKYO MEDICAL UNIVERSITY
发明人： MURAKAMI Yoshiki , KURODA Masahiko
IPC分类号： C12N15/113 , A61K31/7105 , A61K31/7115 , A61K31/712 , A61P1/16
摘要： Provided are an miR-29a-like nucleic acid reagent and a pharmaceutical composition that aim to inhibit liver fibrosis. An miR-29alike nucleic acid reagent according to the present invention includes nucleic acid having a base sequence of Sequence ID No. 1 that includes DNA and RNA and in which at least one nucleotide residue is a modified residue: Sequence ID No. 1: uagcaccaggctgucc. A liver fibrosis inhibitor and a pharmaceutical composition according to the present invention include the miR-29a-like nucleic acid reagent according to the present invention, and are preferably used for oral administration.

3. 发明公开

EP3995154A1 NUCLEIC ACID CARRIER AND METHOD FOR ADMINISTERING NUCLEIC ACID 审中-实审
公开(公告)号：EP3995154A1
公开(公告)日：2022-05-11
申请号：EP20836641.9
申请日：2020-07-03
申请人： TOKYO MEDICAL UNIVERSITY
发明人： KURODA, Masahiko , TAKANASHI, Masakatsu , OHNO, Shin-ichiro , UMEZU, Tomohiro
IPC分类号： A61K48/00 , A61K9/127 , A61K9/51 , A61K47/46 , C12N15/88 , A61K31/7105
摘要： Provided is a novel carrier for introducing a nucleic acid such as a siRNA into a cell. The carrier for a nucleic acid of the present invention includes vesicles from a plant in the family Malpighiaceae, and preferably vesicles derived from acerola. A method for administering a nucleic acid according to the present invention includes forming a conjugate of the carrier for a nucleic acid of the present invention and a nucleic acid and administering the conjugate.

4. 发明公开

EP3284822A1 THERAPEUTIC AGENT FOR EYE DISEASE 审中-公开
标题翻译：治疗眼部疾病的药物
公开(公告)号：EP3284822A1
公开(公告)日：2018-02-21
申请号：EP16780157.0
申请日：2016-04-15
申请人： The University of Tokyo , Tokyo Medical University , Takeuchi, Hirofumi , Bonac Corporation
发明人： TAKEUCHI, Hirofumi , USUI, Tomohiko , KURODA, Masahiko , TAKANASHI, Masakatsu , OHNO, Shinichiro , TOYOFUKU, Hidekazu , TAHARA, Kohei , ONODERA, Risako
IPC分类号： C12N15/09 , A61K9/127 , A61K31/7125 , A61K48/00 , A61P27/02 , C12N15/113
CPC分类号： A61K31/7125 , A61K9/127 , A61K48/00 , A61K48/005 , A61K48/0075 , A61P27/02 , C07H21/02 , C12N15/09 , C12N15/113
摘要： The present invention provides a single stranded nucleic acid molecule represented by the following formula (I):
5'-uagcaccauuugaaaucaguguucc-P-ggaacacugauuucaaauggugcuauu-3' (I)
(SEQ ID NO:1)
wherein -P- shows a proline derivative linker represented by the following formula (Ia):

and
an agent for treating corneal diseases such as ocular surface disorders and the like, comprising the single stranded nucleic acid molecule as an active ingredient.
摘要翻译：本发明提供由下式（I）表示的单链核酸分子：5'-uagcaccauuugaaaucaguguucc-P-ggaacacauauuucaaauggugcuauu-3'（I）（SEQ ID NO：1），其中-P-显示代表脯氨酸衍生物连接体由下述式（Ia）表示的化合物和以单链核酸分子为有效成分的角膜疾病例如眼表疾病等的治疗剂。

5. 发明公开

EP3199542A1 LUNG CANCER DIFFERENTIAL MARKER 有权
标题翻译：肺癌差异性标记
公开(公告)号：EP3199542A1
公开(公告)日：2017-08-02
申请号：EP17158414.7
申请日：2011-09-09
申请人： National Institute of Advanced Industrial Science and Technology , TOKYO MEDICAL UNIVERSITY
发明人： Narimatsu, Hisashi , Togayachi, Akira , Ikehara, Yuzuru , Kaji, Hiroyuki , Kuno, Atsushi , Ohkura, Takashi , Matsuzaki, Hideki , Hirao, Yoshitoshi , Iwaki, Jun , Abe, Minako , Momura, Masaharu , Noguchi, Masayuki
IPC分类号： C07K7/06 , C07K7/08 , C07K14/47 , C07K14/705 , C07K14/78 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/32 , C07K16/40 , C12N9/14 , C12N9/16 , C12N9/26 , C12N9/64 , C12Q1/02 , G01N33/574
CPC分类号： G01N33/6893 , C07K14/4748 , C07K16/28 , C07K16/3023 , G01N33/574 , G01N33/57423 , G01N2440/38
摘要： An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
摘要翻译：本发明的一个目的是开发并提供一种肺癌差异性标记物，其可以方便且高度灵敏地诊断肺癌，而不仅仅取决于癌症患者与健康人之间蛋白质表达水平的增加或减少。本发明的另一个目的是开发和提供能够区分肺癌组织学类型的聚糖标记。在血清糖蛋白中，鉴定了其糖聚糖结构在肺癌细胞培养上清液中特异性改变的糖肽和糖蛋白组，并且它们被提供作为肺癌差异标记。

6. 发明授权

EP2141231B1 METHOD FOR INHIBITION OF SIGNALING THROUGH ErbB2, SIGNALING INHIBITOR FOR USE IN THE METHOD, AND USE OF THE SIGNALING INHIBITOR 失效
标题翻译：一种抑制信号发送关于ERBB2，SIGNALGEBUNGSINHIBITOR FOR USE在该方法和SIGNALGEBUNGSINHIBITORS的使用
公开(公告)号：EP2141231B1
公开(公告)日：2014-03-12
申请号：EP08722734.4
申请日：2008-03-24
申请人： The University of Tokyo , TOKYO MEDICAL UNIVERSITY , National University Corporation Tokyo Medical and Dental University
发明人： GOTOH, Noriko , KURODA, Masahiko , TSUCHIDA, Nobuo , WATANABE, Makoto
IPC分类号： C12N15/09 , A61K31/7088 , A61K38/00 , A61K48/00 , A61P35/00 , C12Q1/02 , C12Q1/68 , G01N33/53
CPC分类号： C12Q1/6886 , A61K31/7088 , A61K38/1709 , A61K39/39558 , A61K48/00 , C07K14/4703 , C07K16/32 , C07K2317/24 , C07K2319/02 , C12N9/1205 , C12Q2600/158 , G01N33/5011 , G01N33/5041 , G01N33/57407 , G01N33/57484 , G01N33/57492 , G01N2333/71 , A61K2300/00

7. 发明授权

EP2281903B1 METHOD FOR EVALUATION OF CANCER BY USING miRNA CANCER MARKER 有权转让
标题翻译：癌症的评估过程中使用的miRNA癌症标志物
公开(公告)号：EP2281903B1
公开(公告)日：2017-01-04
申请号：EP09738852.4
申请日：2009-04-28
申请人： NEC Corporation , TOKYO MEDICAL UNIVERSITY
发明人： KURODA, Masahiko , TANAKA, Masami , OIKAWA, Kosuke , MIZUTANI, Takayuki , TAKANASHI, Masakatsu , IIZUKA, Seiko , KOSUGI, Yoshinori , OHYASHIKI, Kazuma , TSUCHIDA, Akihiko
IPC分类号： C12Q1/68 , C12N15/09
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178

8. 发明公开

EP3088525A1 ARTIFICIAL MATCH-TYPE MIRNA FOR CONTROLLING GENE EXPRESSION AND USE THEREFOR 无效
标题翻译：人工遵守用于控制基因表达及其用途自然资源部TYPE
公开(公告)号：EP3088525A1
公开(公告)日：2016-11-02
申请号：EP14874254.7
申请日：2014-12-27
申请人： Bonac Corporation , TOKYO MEDICAL UNIVERSITY
发明人： KURODA, Masahiko , OHNO, Shinichiro , AOKI, Eriko , YOSHIDA, Yasuhiko , KATO, Shiori , OHGI, Tadaaki
IPC分类号： C12N15/113 , A61K31/7088 , A61K48/00 , A61P35/00 , A61P43/00
CPC分类号： C12N15/113 , A61K31/713 , C12N2310/141 , C12N2310/318 , C12N2310/531
摘要： The present invention provides a new artificial match-type miRNA utilizing miRNA.
A single strand nucleic acid containing X region and Y region, wherein the 3'-terminal of the X region and the 5'-terminal of the Y region are linked via a linker region of a non-nucleotide structure, the X region contains a guide strand sequence of a mature miRNA, and the Y region contains a sequence completely complementary to the X region is an artificial match-type miRNA. The artificial match-type miRNA can suppress expression of the target gene.
摘要翻译：本发明提供了一种新的人工匹配型的miRNA的miRNA利用。单个海滩核酸含有X和Y区域的区域，worin的X区域的3'-末端和Y的5'-末端区经由非核苷酸结构的左侧区域相连时，X区域包含引导成熟miRNA的海滩序列，和Y区域包含互补彻底呼叫到X区的序列是人工匹配类型的miRNA。人工匹配型的miRNA可以抑制靶基因的表达。

9. 发明公开

EP3088524A1 ARTIFICIAL MIMIC MIRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME 审中-实审转让
标题翻译：维多利亚·多芬（KERNSTLICHE MIMIC-MIRNA ZUR STEUERUNG DER GENEXPRESSION UND VERWENDUNG DAVON）
公开(公告)号：EP3088524A1
公开(公告)日：2016-11-02
申请号：EP14873783.6
申请日：2014-12-26
申请人： TOKYO MEDICAL UNIVERSITY
发明人： KURODA, Masahiko , OHNO, Shinichiro
IPC分类号： C12N15/113 , A61K31/7105 , A61P35/00
CPC分类号： C12N15/113 , A61K31/7105 , C12N15/1135 , C12N15/1138 , C12N2310/141 , C12N2320/30
摘要： The present invention provides a novel artificial mimic miRNA utilizing miRNA. An artificial mimic miRNA is a single-stranded nucleic acid including: a X region; and a Y region, the Y region and the X region being linked, wherein the X region is a guide strand sequence of a mature miRNA or a partial sequence of the guide strand sequence of the mature miRNA and consists of a linking side region (X B ) and a non-linking side region (X F ) to the Y region, the linking side region (X B ) is a sequence that does not cause intramolecular annealing within its region, and the Y region is a sequence that intramolecularly anneals to the non-linking side region (X F ) of the X region. According to the artificial mimic miRNA of the present invention, the expression of the target gene can be inhibited.
摘要翻译：本发明提供了一种利用miRNA的新型人造模拟miRNA。人造模拟miRNA是单链核酸，包括：X区; 和Y区，Y区和X区连接，其中X区是成熟miRNA的指导链序列或成熟miRNA的引导链序列的部分序列，并由连接侧区（XB ）和与Y区不同的非连接侧区域（XF），连接侧区域（XB）是在其区域内不产生分子内退火的序列，Y区域是分子内退火的序列， X区域的连接侧区域（XF）。根据本发明的人造模拟miRNA，可以抑制靶基因的表达。

10. 发明公开

EP2423323A1 METHOD FOR EVALUATING CANCER 审中-公开
标题翻译： VERFAHREN ZUR TUMORBEURTEILUNG
公开(公告)号：EP2423323A1
公开(公告)日：2012-02-29
申请号：EP10767100.0
申请日：2010-04-21
申请人： NEC Corporation , TOKYO MEDICAL UNIVERSITY
发明人： KURODA, Masahiko , SAITO, Akira , SANO, Maki
IPC分类号： C12Q1/68 , C12N15/09 , C12Q1/02
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.
摘要翻译：提供了一种使用新型癌症标记物评估受试者的癌症的发病，临床前期，临床阶段或预后的癌症评价方法。使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评估中的新型癌症标志物。检测细胞或组织样品中的癌症标志物，并根据癌症标志物的表达水平评估样品中癌症的可能性。根据该评价方法，通过检测miRNA作为癌症标记物，可以以极好的可靠性来评价样品中癌症的可能性。作为检测癌症标记物的方法，优选使用例如相对于固定化样品的标记探针进行原位杂交法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式